What is Pelican Expression Technology?
Pelican Expression Technology, formerly known as Primrose Bio, Inc., specializes in the Pfenex Expression Technology platform. This robust system is designed for high-yield protein expression, leveraging the Pseudomonas fluorescens system. The company's core offerings encompass therapeutic protein solutions, nucleic acid therapeutics, and mRNA manufacturing, serving a diverse clientele across the biopharmaceutical and industrial sectors. A key component of their service is the Pfast Feasibility Program, which offers rapid, cost-effective early-stage evaluations of molecule compatibility with their proprietary platform. Pelican Expression Technology has established a reputation for efficiently producing complex proteins and collaborates with organizations to overcome protein expression challenges and develop bespoke solutions.
How much funding has Pelican Expression Technology raised?
Pelican Expression Technology has raised a total of $151.4M across 4 funding rounds:
Series A
$24M
Stock Offering
$50M
Stock Offering
$38M
Stock Offering
$39.4M
Series A (2009): $24M with participation from The Dow Chemical Company and Signet Healthcare Partners
Stock Issuance/Offering (2014): $50M, investors not publicly disclosed
Stock Issuance/Offering (2015): $38M, investors not publicly disclosed
Stock Issuance/Offering (2018): $39.4M, investors not publicly disclosed
Key Investors in Pelican Expression Technology
The Dow Chemical Company
The Dow Chemical Company is a global materials science leader, likely investing in Pelican Expression Technology due to potential synergies in chemical and biological manufacturing processes.
Signet Healthcare Partners
Signet Healthcare Partners is a venture capital firm focused on the healthcare industry, suggesting a strategic interest in Pelican Expression Technology's biopharmaceutical and therapeutic protein solutions.
What's next for Pelican Expression Technology?
The recent major strategic investment in Pelican Expression Technology signals a pivotal moment for the company, likely enabling accelerated development of its protein expression technologies and expansion into new markets. With a foundation built on advanced biopharmaceutical solutions and a proven platform, the company is well-positioned to capitalize on the growing demand for efficient therapeutic protein production. Future endeavors may include scaling manufacturing capabilities, forging new strategic partnerships, and further refining their mRNA manufacturing services to address emerging needs in the life sciences industry.
See full Pelican Expression Technology company page
